Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares
Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Baird Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $26
Baird analyst Brian Skorney initiates coverage on $Nurix Therapeutics(NRIX.US)$ with a buy rating, and sets the target price at $26.According to TipRanks data, the analyst has a success rate of 41.0%
Nurix Therapeutics Showcases Breakthrough BTK Degraders
Nurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right Now